Navigation Links
Lupin Launches Ramipril Capsules
Date:6/11/2008

r intellectual property protection. The information presented in this release represents management's expectations and intentions as of this date. Lupin expressly disavows any obligation to update the information presented in this release.
*Altace(R) is a registered trademark of King Pharmaceuticals, Inc.

For More Information:

Contact: Edith St-Hilaire

Senior Marketing Manager

410-576-2000 Ext. 207


'/>"/>
SOURCE Lupin Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3

Related medicine news :

1. Lupin Receives USFDA Approval for Topiramate Tablets
2. CVS Caremark Launches the 2008 Season of the CVS Caremark All Kids Can(TM) Baseball Camps at Fenway Park
3. Miami Institute Launches New Weight Loss Program
4. PointOne Launches New Business Direction, Healthcare Analytics Beyond Hospitals
5. WellPoint Launches and Expands Maternity Depression Program
6. Nutrition 21 Launches Iceland Health(R) Advanced Memory Formula via Direct Response Channel
7. Video: The Nevada Division of Insurance Launches 2008 Health Sham Insurance Campaign
8. Princeton HealthCare System Foundation Launches $115 Million Capital Campaign for New Hospital in New Jersey
9. Cline Davis & Mann Launches Platform Advisors(TM), a New Division to Provide Integrated Strategic and Scientific Consulting Services for the Pharmaceutical, Biotechnology, and Medical Device Industry
10. AVMA Launches Animal Welfare Web Section to Provide Hub for Programs and Information
11. US Oncology Launches Oncology-Specific Billing and Reimbursement Service
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2008)...ment. What do you remember about your breakfast th... smell of coffee brewing, while another will remem...r. How does the brain weave together these fragmen...ife? , Researchers led by Prof. Itzhak Fried, a ...lty of Medicine, are proving scientifically what s...
(Date:12/4/2008)...ird of Americans with diabetes do not know that th...ditions are unaware that they are at risk. A Univ...al tool to identify those at highest risk for havi...ose (IFG) and undiagnosed diabetes. If these condi...rom preventative strategies that can minimize prog...
(Date:12/4/2008)...c. 4 Triple-S,Managemen...it has signed a non-,binding letter of intent to ...zul de Puerto Rico, Inc. In addition, the Company...transfer the licensing rights to the Blue Cross br...ield brands in the US Virgin Islands,to the Compa...
(Date:12/4/2008)...work(TM) to Administer Program , , BUFFALO,...inder(TM) Network has been selected by The Washing...r a Medication Therapy Management (MTM) program fo...UMP) and the Aetna Public Employees Plan of Washin...mmunity pharmacists to review prescriptions with p...
Breaking Medicine News(10 mins):Health News:Unlocking the mysteries of memory 2Health News:Researcher develops screening tool to identify patients with prediabetes 2Health News:Triple-S Management Corporation Signs Letter of Intent to Acquire Managed Care Portfolio of La Cruz Azul de Puerto Rico, Inc. 2Health News:Washington State Health Care Authority to Launch Medication Therapy Management Initiative 2
...n babies and birth weight, it has been found that ...creased liking for salt.// The results of the pres...uals include more salt in their diet than others. ...lthy babies, weighing atleast 2.5 kg. These babies...
... of mothers who are obese before pregnancy or who ...ming overweight at a very young age//. The resea...s the children get older, in a research paper publ.... Dr. Pamela J. Salsberry and Dr. Patricia B. Re...
...ronique Roger, M.D., M.P.H., at the Mayo Cardiolog...e is a high risk of these patients suffering from ...ke risk was 44 times more during the 30 day period...ents when compared to the normal person. The study...
...om color blindness due to X-chromosome variations,...olors but have an increased sensitivity to differe... be differentiated by normal persons. The results ...llon and colleagues, University of Cambridge had b...
Other Medicine News:Health News:Birth Weight of Babies Important Predictor for Salt Preference 2Health News:Kids of overweight mothers have higher obesity risk 2Health News:Colorblind Individuals have expanded color vision 2
(Date:12/3/2008)... Pa., Dec. 3 Wyeth Pharm...nnounced today that it has submitted a,marketing ...dicines Agency,(EMEA) for approval to market its ...vaccine (PCV13) for infants and young children. W...of pneumococcal disease (PD) caused by the 13,ser...
(Date:12/2/2008)... 3 Researchers using fu...uitry in the area of the brain,responsible for su...ering from,stress-related psychiatric disorders. ...he annual meeting of the Radiological Society of N...major depression and other stress-related disorder...
(Date:12/2/2008)... Dec. 2 Horizon Therapeutics, Inc....ay announced that two pivotal,Phase 3 trials eval... HZT-501,met all primary endpoints. HZT-501, a n...containing ibuprofen and famotidine, demonstrated ...dence of non-steroidal,anti-inflammatory drug (NS...
(Date:12/1/2008)...c. 1 TargeGen has announced that a...a multi-center, US-based clinical,trial of TG1013... scheduled at,the 2008 American Society of Hemato...entation are as follows:, Title: ...ble, JAK2-Selective Inhibi...
Breaking Medicine Technology:Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 2Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 3Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 4Wyeth Submits European Marketing Authorization Application for its 13-Valent Vaccine for the Prevention of Pneumococcal Disease in Infants and Young Children 5Stress-Related Disorders Affect Brain's Processing of Memory 2Stress-Related Disorders Affect Brain's Processing of Memory 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 2Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 3Horizon Therapeutics Announces Two Pivotal HZT-501 Phase 3 Trials Meet Primary Endpoints 4Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac 28TM 29 Development at Prestigious International Sympos 2209 1Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac 28TM 29 Development at Prestigious International Sympos 2209 2Access Pharmaceuticals Presents Favorable Ovarian Cancer Data and Clinical Update on ProLindac 28TM 29 Development at Prestigious International Sympos 2209 3Looking tired or angry may have more to do with facial aesthetics than how you feel 20399 1Looking tired or angry may have more to do with facial aesthetics than how you feel 20399 2Oregon Cosmetic Vein Center Opens in Portland Among First on West Coast to Offer Brand New FDA Approved Procedures and Technologies 20397 1Oregon Cosmetic Vein Center Opens in Portland Among First on West Coast to Offer Brand New FDA Approved Procedures and Technologies 20397 2Oregon Cosmetic Vein Center Opens in Portland Among First on West Coast to Offer Brand New FDA Approved Procedures and Technologies 20397 3Buyers Health Care Action Group Pilots New Bridges to Excellence Program for Depression 20395 1Buyers Health Care Action Group Pilots New Bridges to Excellence Program for Depression 20395 2Buyers Health Care Action Group Pilots New Bridges to Excellence Program for Depression 20395 3
...Mar 7, 2007 - Accentia,Biopharmaceuticals, Inc. (N...l Meeting of the American Academy of Allergy, Asth...San Diego, CA. The,posters discussed findings from...rgists in the U.S., U.K., France, and Germany on t... and attitudes of,the fungal etiology of CS, and t...
...r 7, 2007 - BioLineRx Ltd.,(TASE:BLRX), Israel,s l...e-clinical data from trials of BL-1040 demonstrati...ration of the myocardium,after a myocardial infarc...ion and eventual heart failure in a pig model. Pro...Cardiac Research,Institute at Sheba Medical Center...
Other Medicine Technology:Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 2Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 3Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 4Accentia Biopharmaceuticals Scientific Presentations Demonstrate,Increasing Acceptance of Fungal Etiology of Chronic Sinusitis at,the Annual Meeting of the American Academy of Allergy, Asthma, and,Immunology 5BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 2BioLineRx Presents Data on BL-1040 at Cardiovascular,Revascularization Therapies Conference Demonstrating Potential to,Reduce Deterioration of Infarcted Heart Tissue and Maintain,Functionality 3
Aplicare's Prep Pads offer convenience, low cost, ease of use. The medium size is appropriate for most applications. Each package is terminally sterilized, ensuring the safest possible product for th
Triad Plus PVP-I Scrub swabsticks is formulated with an antimicrobial surgical cleanser containing to prevent dryness. It contains 7.5% PVP-I, USP solution equivalent to 0.75% available iodin
...are saturated with a 10% Povidone Iodine, USP ...vidone Iodine is virtually non-irritating to skin,...g to the skin or natural fabrics. Our swabsticks n...tools for removing small particles from wounds, su...
BD Persist Plus protective barrier provides a one-step antimicrobial barrier with minimum of 1% chlorhexidine with Up to 7-day antimicrobial effectiveness.
Medicine Products: